Press coverage about Akorn (NASDAQ:AKRX) has trended somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Akorn earned a news sentiment score of 0.15 on Accern’s scale. Accern also gave media coverage about the company an impact score of 45.764655790069 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the news headlines that may have effected Accern Sentiment Analysis’s scoring:
- Analyzing Akorn (AKRX) & Its Rivals (americanbankingnews.com)
- Breakfast Technical Briefing on Generic Drugs Stocks — Mallinckrodt, Akorn … (prnewswire.com)
- Short Interest in Akorn, Inc. (AKRX) Increases By 14.2% (americanbankingnews.com)
- Breakfast Technical Briefing on Generic Drugs Stocks — Mallinckrodt, Akorn, Pacira Pharma, and Rigel Pharma (bizjournals.com)
A number of research firms have recently commented on AKRX. Jefferies Group LLC reiterated a “hold” rating and issued a $34.00 price objective on shares of Akorn in a research note on Wednesday, July 19th. Piper Jaffray Companies set a $34.00 price target on Akorn and gave the company a “hold” rating in a research note on Sunday, October 22nd. BidaskClub lowered Akorn from a “buy” rating to a “hold” rating in a research note on Monday, July 24th. Royal Bank Of Canada restated a “sector perform” rating and set a $34.00 price target on shares of Akorn in a research note on Sunday, August 20th. Finally, TheStreet lowered Akorn from a “b-” rating to a “c” rating in a research note on Tuesday, August 1st. Three research analysts have rated the stock with a sell rating, nine have given a hold rating and one has assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $29.38.
Shares of Akorn (NASDAQ AKRX) traded up $0.06 on Wednesday, hitting $33.37. The stock had a trading volume of 980,800 shares, compared to its average volume of 2,776,148. The company has a quick ratio of 3.17, a current ratio of 4.16 and a debt-to-equity ratio of 0.92. Akorn has a fifty-two week low of $17.61 and a fifty-two week high of $34.00. The firm has a market cap of $4,166.10, a P/E ratio of 20.69, a P/E/G ratio of 1.98 and a beta of 1.33.
Akorn Company Profile
Akorn Inc (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two segments: Prescription Pharmaceuticals and the Consumer Health.
Receive News & Ratings for Akorn Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akorn Inc. and related companies with MarketBeat.com's FREE daily email newsletter.